NCT00416442已完成1 期
A Randomized, Double-blind Placebo-controlled Single- to Multiple-dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of RSV604 Intravenous Formulation in Healthy Subjects
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 48
- 试验地点
- 1
- 主要终点
- Safety and tolerability of single and multiple intravenous doses of RSV604 as measured by vital signs, electrocardiographs (ECGs), adverse events, clinical laboratory evaluations.
研究概览
简要总结
This study is designed to evaluate the safety, tolerability and pharmacokinetics of single and multiple-dose escalation of RSV604 administered intravenously in healthy subjects.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 50 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy male and female subjects, 18-50 years of age, in good health as determined by past medical history, physical examination, vital signs, electrocardiogram, and laboratory tests at screening.
- •Vital signs within the following parameters:
- •oral body temperature between 35.0-37.5 °C systolic blood pressure, 85-140 mm Hg diastolic blood pressure, 50-90 mm Hg pulse rate, 40 - 100 beats per minute (bpm)
- •Female subjects must have been surgically sterilized at least 6 months prior to screening, with supportive clinical documentation OR Postmenopausal women must have no regular menstrual bleeding for at least 1 year prior to inclusion.
- •Body mass index (BMI) must be within the range of 18 to 30 kg/m
- •Subjects must weigh at least 50 kg to participate in this study.
排除标准
- •Smokers (use of tobacco products in the previous 3 months). Smokers will be defined as any subject who reports tobacco use or has a urine cotinine greater than 300 ng/ml
- •Participation in any clinical investigation involving medical intervention within 4 weeks before study start
- •Donation or loss of 400 ml or more of blood within 8 weeks prior to before study start
- •Significant illness within 2 weeks before study start
- •A past personal or close family medical history of clinically significant ECG abnormalities or of a prolonged QT-interval syndrome.
- •History of autonomic dysfunction (e.g. history of fainting, orthostatic hypotension).
- •History of acute or chronic bronchospastic disease (including asthma and chronic obstructive pulmonary disease, treated or not treated),
- •History of clinically significant drug allergy or history of atopic allergy (asthma, urticaria, eczematous dermatitis). A known hypersensitivity to the study drug or drugs similar to the study drug particularly benzodiazepines.
- •Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism or excretion of drugs or which may jeopardize the subject in case of participation in the study, including bowel, gastrointestinal, renal, pancreatic, hepatic, hematological, immunological, or neurological disorders.
- •Other protocol-defined inclusion/exclusion criteria may apply
结局指标
主要结局
Safety and tolerability of single and multiple intravenous doses of RSV604 as measured by vital signs, electrocardiographs (ECGs), adverse events, clinical laboratory evaluations.
Tolerability of single and multiple intravenous doses of RSV604, RSV604 as measured by vital signs, ECGs, adverse events, clinical laboratory evaluations
次要结局
- Pharmacokinetics of single-dose RSV604 intravenous formulation administered orally and intravenously
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Study to Determine the Effect of Multiple Oral Doses of SLx-2119 in Healthy Male SubjectsImmune System Disorder (Healthy Volunteer)NCT05918627Kadmon, a Sanofi Company32
已完成
1 期
Safety and Pharmacokinetics of Single and Multiple Ascending Doses of 3K3A-APC in Healthy Adult VolunteersHealthyNCT01660230ZZ Biotech, LLC64
终止
1 期
The Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of BWC0977 in Healthy Adult VolunteersInfectious DiseasesBacterial InfectionsNCT05942820Bugworks Research Inc.4
已完成
1 期
A First in Human Study of the Safety and Tolerability of Single and Multiple Doses of BWC0977 in Healthy VolunteersInfectious DiseasesBacterial InfectionsNCT05088421Bugworks Research Inc.44
已完成
1 期
Safety, Tolerability, and Pharmacokinetics of Multiple-Dose TAK-058 in Healthy ParticipantsHealthy VolunteersNCT02389881Takeda40